Negotiating commissioning pathways for the successful implementation of innovative health technology in primary care

• Main Authors: Gregory Maniatopoulos (Author), Shona Haining (Author), John Allen (Author), Scott Wilkes (Author)
• Format: Knjiga
• Izdano: BMC, 2019-09-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.
• Notes: 10.1186/s12913-019-4477-3; 1472-6963
• Keywords: Commissioning; Decision-making; Diagnostics; Innovative health technologies; Primary care; Peripheral arterial disease; Public aspects of medicine; RA1-1270
• Source: BMC Health Services Research, Vol 19, Iss 1, Pp 1-12 (2019)

Abstract Background Commissioning innovative health technologies is typically complex and multi-faceted. Drawing on the negotiated order perspective, we explore the process by which commissioning organisations make their decisions to commission innovative health technologies. The empirical backdrop to this discussion is provided by a case study exploring the commissioning considerations for a new photoplethysmography-based diagnostic technology for peripheral arterial disease in primary care in the UK. Methods The research involved an empirical case study of four Clinical Commissioning Groups (CCGs) involved in the commissioning of services in primary and secondary care. Semi-structured in-depth interviews (16 in total) and two focus groups (a total of eight people participated, four in each group) were conducted with key individuals involved in commissioning services in the NHS including (i) senior NHS clinical leaders and directors (ii) commissioners and health care managers across CCGs and (iii) local general practitioners. Results Commissioning of a new diagnostic technology for peripheral arterial disease in primary care involves high levels of protracted negotiations over funding between providers and commissioners, alliance building, conflict resolution and compromise of objectives where the outcomes of change are highly contingent upon interventions made across different care settings. Our evidence illustrates how reconfigurations of inter-organisational relations, and of clinical and related work practices required for the successful implementation of a new technology could become the major challenge in commissioning negotiations. Conclusions Innovative health technologies such as the diagnostic technology for peripheral arterial disease are commissioned in care pathways where the value of such technology is realised by those delivering care to patients. The detail of how care pathways are commissioned is complex and involves high degrees of uncertainty concerning such issues as prioritisation decisions, patient benefits, clinical buy-in, value for money and unintended consequences. Recent developments in the new care models and integrated care systems (ICSs) in the UK offer a unique opportunity for the successful commissioning arrangements of innovative health technologies in primary care such as the new diagnostic technology for peripheral arterial disease.